SciBase Holding AB (publ)
STO:SCIB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (16.2), the stock would be worth kr-1.32 (423% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5 | kr0.41 |
0%
|
| Industry Average | 16.2 | kr-1.32 |
-423%
|
| Country Average | 21.3 | kr-1.74 |
-526%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
S
|
SciBase Holding AB (publ)
STO:SCIB
|
338.8m SEK | -5 | -3.9 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.6B USD | 65.3 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
155.4B USD | 29 | 24.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
112.7B USD | 20.7 | 34.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
102.7B USD | 27.3 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
83.8B USD | 29.3 | 23.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.8B USD | 37 | 44.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 41.4 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.2B USD | 46 | 42.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.5B USD | 17.6 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
29.9B USD | 17.2 | 20.1 |
Market Distribution
| Min | 0.6 |
| 30th Percentile | 12.2 |
| Median | 21.3 |
| 70th Percentile | 31.9 |
| Max | 19 008.8 |
Other Multiples
SciBase Holding AB (publ)
Glance View
SciBase Holding AB is a global medical technology company, which engages in the development and sale of instruments for the detection of skin cancer and other skin diseases. The company is headquartered in Sundbyberg, Stockholm and currently employs 23 full-time employees. The company went IPO on 2015-06-02. The firm specializes in the manufacture of point of care device, called Nevisense, which is aimed to detect of malignant melanoma. Nevisense analyze suspicious lesions by using Electrical Impedance Spectroscopy (EIS) which is applied as an electrical signal to the skin. The diagnostic product is sold in Nordic countries, Belgium, Germany, Great Britain and Australia.
